To elucidate the effects of synthetic salmon calcitonin (sCT) on the cells in the rat pituitary gland, we histopathologically and immunohistochemically examined the early changes after 4 or 13 weeks treatment with sCT 120IU/kg.
RECENTLY,
we reported that administration of synthetic salmon calcitonin (sCT) for 1 year resulted in an increase in pituitary gland hyperplasia and adenomas in Sprague-Dawley rats [11 . Furthermore, we demonstrated that only the alpha-subunit was stained by the immunoperoxidase method in the pituitary tumors induced by sCT [1] . Therefore, we postulated that sCT-induced pituitary tumors were endocrinologically non-functioning and alphasubunit-producing tumors [1] . Some pituitary tumors are not associated with the hypersecretion of hormones.
Because a specific Received: July 13, 1999 Accepted: October 25, 1999 tumor marker has yet to be found, the diagnosis of non-functioning chromophobe adenoma is not made in these patients until the tumors are so large that they produce visual loss and other compressive symptoms.
Similarly, it is difficult to assess the completeness of pituitary surgery and to monitor these patients after radiotherapy [2] [3] [4] [5] [6] . Their follow-up examination to evaluate tumor recurrence is limited to visual field changes or radiographic abnormalities [2] [3] [4] [5] [6] In the present study, in order to confirm the biological significance of sCT-induced rat pituitary tumor, we histopathologically and immunohistochemically examined the early changes after 4 or 13 weeks treatment with sCT.
Materials and Methods

Animals and tissue preparation
Male Sprague-Dawley rats were purchased from Charles River Japan Inc. (Atsugi, Japan) at the age of five weeks. The animals were kept in a barrierdivided room, which was maintained at a temperature of 22±2°C with a humidity of 60± 10%. The room was ventilated 23 times per h and provided with 12 h of light (from 8 : 00 to 20 : 00). The animals were housed in individual plastic cages (CLEA Japan Inc.). Solid food (CE-2, CLEA Japan Inc.) and tap water were available to all animals ad libitum. One week was allowed for the animals to adjust to laboratory conditions.
The sCT (Teikoku Hormone Mfg. Co., Ltd., Kawasaki) is a type I form of naturally produced salmon calcitonins [7] , and has a potency of about 5,000lU/mg.
The sCT was dissolved in an acetic acid buffer (pH 4.0).
Twenty animals were used as untreated controls. Twenty rats each received daily administration of vehicle or sCT (120IU/kg/day) by subcutaneous injection for 4 or 13 weeks. Each rat was sacrificed on the day after the last injection under ether anesthesia. The pituitary glands were removed immediately.
Histopathological examination
The pituitary glands were fixed in 0. After the completion, the sections were treated with Graham-Karnovsky's reaction medium [8] , which contained 20 mg% 3,3"-diaminobenzidine (DAB, Wako Pure Chemical Industries, Osaka) and 0.005% hydrogen peroxide in 0.05 M Tris-HC1 buffer, pH 7.6, for 5 to 10 min at room temperature. The sections were then counterstained for nuclei with 1% methyl green dissolved in veronal acetate buffer, pH 4.2.
Anti-rPit-1 antibody was obtained from Santa Cruz Biotechnology Inc. After deparafl'inization, the endogenous peroxidase was blocked with 0.1% hydrogen peroxide-methanol for 30 min at room temperature and the sections were then pretreated by microwaving for 10 min in 0.01 M citrate buffer, pH 6.0, for antigen retrieval. After washing with 0.01 M phosphate-buffered saline (PBS), the sections were incubated for 1 h at room temperature with rabbit polyclonal antibody against rat Pit-1 protein diluted at 1: 200. After washing with 0.01 M PBS, the sections were covered with biotin-conjugated goat anti-rabbit IgG for 1 h, washed again and then treated with streptavidin-biotin-peroxidase complex (Histofine SAB-PO(R)Kit, Nichirei, Tokyo) for 1 h. After washing with 0.01 M PBS, the immnoperoxidase staining was performed as described above. Histologically, the cells which make up the focal proliferative lesions were classified into the following groups: 1) enlarged basophilic cell focus (Fig. 1A) , 2) vacuolated cell focus (Fig. 1B) and 3) chromophobe cell focus (Fig. 1C) . The sCT treatment also increased the thickness of the pars intermedia without inducing any disorder of the lobular structure or degeneration of the pars intermediate (Figs. 2A, B) . Compared with that in the vehicle-treated rats, the mean cell size was significantly increased in the rats treated with sCT for 4 weeks (Table 1) stained only for alpha-subunit by the immunoperoxidase method.
The mature pituitary is composed of six different types of cells, five in the anterior lobe and one in the intermediate lobe, that appear sequentially during development and are easily distinguishable by the hormone secreted [9] . The glycoprotein hormone alpha-subunit is the first hormone subunit to be expressed in the developing mouse pituitary on embryonic day 11.5 (el1.5), followed by anterior pituitary POMC on e12, TSH on e14, intermediate lobe POMC for MSH synthesis on e14.5, GH and PRL on e15.5, LH on e16.5, and FSH on e17.5 [10] [11] [12] . In the rat pituitary, alpha-subunit appears on embryonic day 11 (ell) as the first anterior pituitary marker [9] , and alpha-subunit expression is restricted to the anterior most pituitary The majority of the nuclei in the hypertrophic pars intermedia induced by sCT are positivity stained for Pit-1 protein. Peroxidase-labeled antibody method x 100. cells at this stage [9] . Recent studies on the ontogeny of pituitary cell development in the rat indicate that expression of the alpha-subunit gene precedes that of the other hormone genes by several days and in fact occurs early in the formation of Rathke's pouch [9] . Thus, the alpha-subunit producing cells may be relatively primitive pituitary cells with some characteristics of stem cells.
In the present study, focal proliferative lesions induced by sCT failed to show Pit-1 protein.
In . We found that the sCT treatment produced an increase in the thickness of the pars intermedia, and that the mean cell size was significantly increased. Horiuchi et al. [i7] demonstrated that the daily administration of sCT (120 IU/kg) for 3, 7 and 14 days produced 2.8-, 2.6-, and 2.3-fold increase, respectively, in the rate of cell proliferation as estimated by BrdU labeling. This increase after sCT treatment is thought to be indicative of hyperfunction of the pars intermedia, since haloperidol, a D-2 dopamine receptor antagonist which enhances pars intermedia function, increases and bromocriptin, a D-2 agonist which inhibits the pars intermedia, decreases the rates of cell proliferation as determined by the uptake of No difference was seen. Based on our findings and these facts, the morphological changes after sCT treatment strongly suggest that sCT enhances the activity of pars intermediate cells of the rat pituitary gland.
Recent studies with transgenic mice deficient in P27 has shown that this protein inhibits proliferation in some tissues such as the thymus, pituitary, and spleen leading to hyperplasia of these tissues and an increase in general body weight, despite normal levels of serum GH and insulin-like growth factor-1 when P27 was absent [19] . Interestingly, the pituitary of transgenic mice with P27 gene deletion showed ACTH cell hyperplasia from the intermediate lobe. It is well documented that calcitonin is involved in calcium regulation in mammals, mainly by inhibiting osteolysis.
The sCT is a peptide hormone composed of 32 amino acid residues.
In mammals, maintenance of the extracellular calcium ion concentration within narrow limits is essential for the function of many tissues.
In addition, calcium ions are also essential for the secretory activity of endocrine and exocrine cells. Furthermore, calcium is an important and ubiquitous regulator of various intracellular enzyme activities.
As focal proliferative lesions of the anterior pituitary glands are induced by sCT, we cannot determine from the present study whether the effects of sCT are direct or indirect.
It is possible that one of the many systemic physiological effects of sCT leads indirectly to the proliferation of a subset of a pituitary cell-type.
It is notable that calcitonin is produced in large amounts in the posterior hypothalamus and median eminence, raising the possibility that calcitonin may normally exert effects on the hypothalamus-pituitary axis [20, 2i] . Calcitonin receptors have been identified in the hypothalamus, and lower numbers of receptors are found in the pituitary gland [21] . Infusion of calcitonin in rats has been reported to cause a reduction in several pituitary hormones including GH, PRL, LH, FSH, and TSH [22] . The mechanism for these effects has not been elucidated and it remains to be shown whether sCT is acting at the hypothalamic or pituitary level. In dispersed pituitary cells, calcitonin has been shown to inhibit TRH stimulation of PRL secretion [23] , suggesting that some of the effects of sCT may occur directly at the level of the pituitary.
The pars intermedia is known to be regulated primarily by dopaminergic neurons emanating from the arcuate nucleus of the hypothalamus and terminating directly on pars intermediate cells [24] . Thus, pharmacological manipulation with dopaminergic drug has been shown to elicit changes in the rat pars intermediate cells morphology, secretion of POMC-derived peptide, POMC mRNA content, and rate of cell proliferation [25] [26] [27] . Future studies must determine the mechanistic relationships between POMC or Pit-1 gene expression and cellular proliferation induced by sCT.
